Global Whole Exome Sequencing Market Growth (Status and Outlook) 2023-2029

Global Whole Exome Sequencing Market Growth (Status and Outlook) 2023-2029

Exome sequencing is a capture based method developed to identify variants in the coding region of genes which affect protein function. While exome capture methods using PCR, hybrid capture and molecular inversion probes exist, the most common and efficient strategies are in-solution capture methods. In-solution capture utilizes pools of oligonucleotides or probes bound to magnetic beads, whose sequence has been designed to hybridize to exon regions. After binding to genomic DNA, these probes are pulled down and washed, allowing exon regions to be selectively sequenced.
While there are approximately 180,000 exons in the human genome, constituting less than 2% of total sequence, the exome contains ~80-90% of known disease causing variants making it a cost-effective alternative to whole genome sequencing. When performing exome-seq, users should not only consider average on-target coverage but also the local coverage of particular sites of interest. When choosing between exome and whole genome sequencing (WGS), consider that exome sequencing has the advantage that oligonucleotides are designed to particular genomic regions where typical coverage with WGS is not enough for SNP calling. It is also more affordable enabling the analysis of more individuals and populations. With WGS, you can detect variants in regions not covered by exome capture allowing or the identification of structural and non-coding variants associated with disease.
LPI (LP Information)' newest research report, the “Whole Exome Sequencing Industry Forecast” looks at past sales and reviews total world Whole Exome Sequencing sales in 2022, providing a comprehensive analysis by region and market sector of projected Whole Exome Sequencing sales for 2023 through 2029. With Whole Exome Sequencing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Whole Exome Sequencing industry.
This Insight Report provides a comprehensive analysis of the global Whole Exome Sequencing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Whole Exome Sequencing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Whole Exome Sequencing market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Whole Exome Sequencing and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Whole Exome Sequencing.
The global Whole Exome Sequencing market size is projected to grow from US$ 289.6 million in 2022 to US$ 633.2 million in 2029; it is expected to grow at a CAGR of 11.8% from 2023 to 2029.
The major players in global Whole Exome Sequencing market include Illumina, Thermofisher, Roche, etc. The top 3 players occupy about 45% shares of the global market. North America and Europe are main markets, they occupy about 70% of the global market. Illumina TruSeq Exome and Roche Nimblegen SeqCap are main types, with a share about 55%. Mendelian Disease and Rare Syndrome Gene Discovery are the main application, which hold a share about 40%.
This report presents a comprehensive overview, market shares, and growth opportunities of Whole Exome Sequencing market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
Agilent HaloPlex
Agilent SureSelect
Agilent SureSelect QXT
Illumina TruSeq Exome
Roche Nimblegen SeqCap
MYcroarray MYbaits
Segmentation by application
Correlation Research of Normal Human
Mendelian Disease and Rare Syndrome Gene Discovery
The Research of Complex Diseases
Mouse Exome Sequencing
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Illumina
Thermo Fisher
Roche
Angilent
Eurofins
Sengenics
Ambry
Macrogen
BGI
Novo Gene

Please note: The report will take approximately 2 business days to prepare and deliver.